Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

"Dementia prevention" innovation to be trialled in US

03.12.2004


A vitamin B pill that drastically lowers blood levels of the toxic amino-acid homocysteine could one day be used to prevent dementia, and save health services billions of pounds annually.



Clinical trials, starting in January 2005, will seek to confirm that adding the B vitamins to a powerful antioxidant results in “prompt, striking and sustained clinical improvement” in patients. The move follows a licensing agreement this week between COBALZ Limited, a U.K. company specialising in homocysteine research, and Pamlab L.L.C, a U.S. company providing high-quality pharmaceuticals for general practices, neurology, cardiology and internal medicine.

It will enable a team led by Dr. Ramon Diaz-Arrastia of the University of Texas Southwestern Medical Center, to determine whether the antioxidant together with high-dose B vitamins is superior to standard B-vitamin supplements in slowing the rate of cognitive decline and the accumulation of MRI abnormalities in Alzheimer’s disease patients.


High blood levels of homocysteine are a risk factor for stroke and dementia, including Alzheimer’s disease. Raised levels damage nerves and blood vessels, and lead to a loss of brain tissue in patients. Although homocysteine can be lowered by standard B vitamin supplements it is not yet known whether these can be used to treat or prevent dementia. The few small studies to date are disappointing.

However, dementia is also associated with ‘free radicals’ which oxidise and damage an enzyme that breaks down homocysteine. COBALZ has found that adding a powerful antioxidant to B vitamins lowers homocysteine levels even further and results in prompt, striking and sustained clinical improvement in patients.

Neil McCaddon, Global Head of Licensing & Corporate Development for COBALZ, said: “We are very excited about the possibilities, and hope to announce some real breakthroughs for sufferers of dementia, and their carers.” Barry LeBlanc, President of Pamlab L.L.C., said: “Pamlab is very excited to incorporate COBALZ technology into its product line addressing hyperhomocysteinemia, and its role in mild cognitive impairment, vascular dementia and Alzheimer’s disease.”

Alzheimer’s disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone. COBALZ is now actively seeking other licensing and development partners for the rest of the global market.

Neil McCaddon | alfa
Further information:
http://www.cobalz.co.uk

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

Leipzig HTP-Forum discusses "hydrothermal processes" as a key technology for a biobased economy

12.07.2017 | Event News

 
Latest News

Researchers create new technique for manipulating polarization of terahertz radiation

20.07.2017 | Information Technology

High-tech sensing illuminates concrete stress testing

20.07.2017 | Materials Sciences

First direct observation and measurement of ultra-fast moving vortices in superconductors

20.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>